OTAVA-BB BB7020410011
|
- $217 - $863
- Product name: OTAVA-BB BB7020410011
- CAS: 90007-75-3
- MF: C8H10N2O4
- MW: 198.18
- EINECS:
- MDL Number:MFCD08143647
- Synonyms:OTAVA-BB BB7020410011;Methyl 3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propanoate;methyl 3-(2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl)propanoate;1(2H)-Pyrimidinepropanoic acid, 3,4-dihydro-2,4-dioxo-, methyl ester
3 prices
Selected condition:
Brand
- Chemenu
Package
- 100mg
- 250mg
- 1g
- ManufacturerChemenu
- Product numberCM337955
- Product descriptionMethyl3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propanoate 95%+
- Packaging100mg
- Price$217
- Updated2021-12-16
- Buy
- ManufacturerChemenu
- Product numberCM337955
- Product descriptionMethyl3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propanoate 95%+
- Packaging250mg
- Price$370
- Updated2021-12-16
- Buy
- ManufacturerChemenu
- Product numberCM337955
- Product descriptionMethyl3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propanoate 95%+
- Packaging1g
- Price$863
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Chemenu | CM337955 | Methyl3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propanoate 95%+ | 100mg | $217 | 2021-12-16 | Buy |
| Chemenu | CM337955 | Methyl3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propanoate 95%+ | 250mg | $370 | 2021-12-16 | Buy |
| Chemenu | CM337955 | Methyl3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propanoate 95%+ | 1g | $863 | 2021-12-16 | Buy |
Properties
Melting point :116-117 °C(Solv: ethanol (64-17-5))
Density :1.287±0.06 g/cm3(Predicted)
storage temp. :Store at Room Tem.
pka :9.51±0.10(Predicted)
Density :1.287±0.06 g/cm3(Predicted)
storage temp. :Store at Room Tem.
pka :9.51±0.10(Predicted)
Safety Information
| Symbol(GHS): |
|
||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | ||||||||||||||||||||||||||||||||
| Hazard statements: |
|
||||||||||||||||||||||||||||||||
| Precautionary statements: |
|




